You are here: Home » Companies » News
Business Standard

Biocon Q1 net profit rises 72% to Rs 206 crore; total income up 25%

Net profit, excluding exceptional item, stood at Rs 223 crore reporting growth of 86 per cent

Gireesh Babu 

Biocon logo

has posted a 72 per cent increase in net profit at Rs 206.3 crore during the quarter ended June 30, 2019, compared to Rs 119.7 crore registered during the same period of last year. The total income on a consolidated basis grew 25 per cent to Rs 1,490 crore during the quarter from Rs 1,192.6 crore a year ago, backed by the performance in biologics and small molecules business. Net profit, excluding exceptional item, stood at Rs 223 crore reporting growth of 86 per cent and it was impacted due to an exceptional item on account of tax on group entities restructuring, said the company.

The Small Molecules business reported a revenue growth of 20 per cent for the quarter at Rs 480 crore, led by sales of its key Active Pharmaceutical Ingredients (API) and a multi-fold of its Generic Formulations business. Revenue from the Research Services business this quarter stood at Rs 421 crore driven by Discovery Services and Dedicated R&D Centre businesses. Syngene, the research services company, is setting up a new research centre in Hyderabad to support its long term growth strategy.

"Our long-term investments in biosimilars are delivering expected results as demonstrated by the 96 per cent growth in our Biologics revenue at Rs 490 crore this quarter, led by the expansion of our geographical footprint and increased penetration of our products in key developed and emerging market," said Kiran Mazumdar-Shaw, chairperson and managing director, Ltd.

However, the Branded Formulations business, which includes sales in India and UAE, reported a de-growth of 9 per cent at Rs 133 crore, as uncertainty in the UAE market continued to weigh down the overall performance of this segment. The company's business in UAE continued to be impacted due to re-pricing of branded generic products mandated by the Ministry of Health, it said.

The company continued to grow its business in the US and other developed markets. Fulphila, the biosimilar Pegfilgrastim co-developed by and Mylan, captured 21 per cent volume share of the Pegfilgrastim syringes market in the US till May, 2019.

First Published: Thu, July 25 2019. 21:43 IST